Alimta Injection, Powder, Lyophilized, For Solution
Product Images NDC 0002-7640

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Alimta (NDC 0002-7640). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Alimta 100mg 011 03

This is a description of a medication called Pemetrex, which is available in injection form. It is equivalent to 100 mg of pemetrexed, 0.6 mg of mannitol, hydrochloric acid, and sodium. The medication should be added to a suitable temperature and reconstituted before use. The text also provides instructions for reconstitution and administration of the medication. Caution needs to be taken while handling the drug as it is cytotoxic. The accompanying information needs to be referred to for usage purpose.*

FDA Label Image

Alimta 500mg 010 03

This appears to be a product literature for the drug "Pemetrexed" used for injection for medical purposes. It provides instructions on how to prepare for injection and possible storage for the drug. The text contains a cautionary warning indicating that the drug is cytotoxic and was likely produced by Ly USA LG.*

FDA Label Image

Structural Formula (Alimta F01 V01)

FDA Label Image

Figure 1 (Alimta F05 V04)

This appears to be a table displaying data on two chemotherapy treatment options for cancer, AUMTA + Cisplatin (AC) and Gemcitabine + Cisplatin (GC), along with information on survival probability, survival time in months, and the number of patients at risk for each treatment. It is not possible to determine what specifically the numbers represent without more context.*

FDA Label Image

Figure 2 (Alimta F08 V3)

FDA Label Image

Figure 4 (Alimta F12 V3)

This appears to be a data chart describing survival probabilities and times for ALIMTA (a medication) and Placebo (a control group) over a period of months. The numbers correspond to the count of patients, and percentage of those who survived or died, along with the time span.*

FDA Label Image

Figure 5 (Alimta F13 V2)

This appears to be a table showing survival probability and patients at risk for a clinical trial involving ALIMTA and a placebo treatment. The data includes the number of patients in each group, survival times in months, and potentially some errors or missing values. However, the formatting is unclear and some of the characters are unreadable, so further interpretation may be difficult.*

FDA Label Image

Figure 7 (Alimta F14 V2)

This appears to be a survival analysis table that includes the number of patients who received ALIMTA and a placebo treatment, their survival time in months, and the number of patients at risk at each time point. However, the table is not complete and some values are missing or unreadable, making the description of the analysis difficult.*

FDA Label Image

Figure 3 (Alimta F15 V01)

This appears to be a table of data with information on two different treatment options for patients, referred to as "ALIMTA+Gisplatin (AC)" and "Gemeitabine+Cisplatin (GC)." There are numbers listed under the "Survival Time" column, which suggests that this table is measuring how long patients in each group survived. There are also numbers listed under "Patients at Risk" for each group, which may refer to the number of patients who were still in the trial at different time points. Without additional context, it is difficult to draw any specific conclusions from this data.*

FDA Label Image

Figure 6 (Alimta F16 V1)

This is a table displaying data related to survival probability, patients at risk, and survival time for patients receiving treatment with ALIMTA and Dlacite. The table shows the number of patients at risk, survival time in months, and survival probability percentages. The table also includes codes such as "pos" and "w2 2," which may need further context to understand their meaning.*

FDA Label Image

Figure 8 (Alimta F17 V1)

This text is a comparison of survival time between patients treated with ALIMTA+ Cisplatin and those without. The graph shows the number of patients at risk in each group at different time intervals, measured in months. The text includes some chemical components, such as Cisplatin.*

FDA Label Image

Alimta F18 V1

This is a graph that shows the overall survival percentage at different time intervals, ranging from 0 to 21 months, for two treatment arms: A+P+C, which stands for ALIMTA + pembrolizumab + platinum chemotherapy, and A+C, which stands for ALIMTA + platinum chemotherapy + placebo. The number of individuals at risk is given for each time interval.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.